SCHEMBL23980935

SCHEMBL23980935

Fc1cc(Cl)ccc1C1COc2c(Br)cccc2O1

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 9/20 0.39
CYP11B2 P19099 9/20 0.39
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
FFAR1 O14842 2/20 0.33
CA2 P00918 1/20 0.33
NPC1 O15118 1/20 0.32
HPGD P15428 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
ADRA2A P08913 1/20 0.32
ADRA2B P18089 1/20 0.32
ADRA2C P18825 1/20 0.32
GRM2 Q14416 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30275367 1.00 CYP11B1 (0.39) CYP11B1CYP11B2HTR2AHTR2CHTR2B
SCHEMBL29924349 0.90 HTR2A (0.37) CYP11B1CYP11B2HTR2AHTR2CHTR2B
SCHEMBL24186456 0.90 HTR2A (0.37) CYP11B1CYP11B2HTR2AHTR2CHTR2B
SCHEMBL23980833 0.90 HTR2A (0.37) CYP11B1CYP11B2HTR2AHTR2CHTR2B
SCHEMBL30680708 0.88 MAP3K14 (0.38) HTR2AHTR2CHTR2BNPC1HPGD
SCHEMBL29924775 0.82 MAPT (0.44) HTR2AHTR2CHTR2BNPC1HPGD
SCHEMBL28949266 0.81 ADRA2A (0.52) CYP11B1CYP11B2HTR2AHTR2CHTR2B
SCHEMBL30217488 0.81 ADRA2A (0.52) CYP11B1CYP11B2HTR2AHTR2CHTR2B
SCHEMBL30680666 0.80 MAP3K14 (0.41) HTR2AHTR2CHTR2BNPC1HPGD
SCHEMBL23980818 0.80 LTA4H (0.40) CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552791-B2 Heterocyclic GLP-1 agonists GASHERBRUM BIO, INC. (US) 2026-02-17 US disclosed
EP-4143183-B1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO INC (US) 2025-10-22 EP disclosed
US-20250214999-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2025-07-03 US disclosed
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2023-09-21 US disclosed
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2023-09-21 US disclosed
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2023-09-21 US disclosed
WO-2021219019-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR CYP11B1 970/4885CYP11B2 1576/4885HTR2A 181/4885
US-12552791-B2 Heterocyclic GLP-1 agonists GLP1R, NPY1R, NPY2R CYP11B1 474/4885CYP11B2 648/4885HTR2A 436/4885
US-20250214999-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR CYP11B1 970/4885CYP11B2 1576/4885HTR2A 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.